NASDAQ:DMRA Damora Therapeutics, Inc. Common Stock Q1 2026 Earnings Report $33.27 +0.28 (+0.85%) As of 09:57 AM Eastern ProfileEarnings HistoryForecast Damora Therapeutics, Inc. Common Stock EPS ResultsActual EPS-$0.62Consensus EPS -$0.39Beat/MissMissed by -$0.23One Year Ago EPSN/ADamora Therapeutics, Inc. Common Stock Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ADamora Therapeutics, Inc. Common Stock Announcement DetailsQuarterQ1 2026Date5/13/2026TimeAfter Market ClosesConference Call DateTuesday, May 12, 2026Conference Call Time7:00AM ETUpcoming EarningsDamora Therapeutics, Inc. Common Stock's Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedules, with a conference call scheduled on Monday, August 3, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Damora Therapeutics, Inc. Common Stock Earnings HeadlinesDamora Announces Redomestication from Delaware to Cayman IslandsJuly 17, 2026 | globenewswire.comDamora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Average Recommendation of "Moderate Buy" by AnalystsJuly 14, 2026 | americanbankingnews.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.July 21 at 1:00 AM | Banyan Hill Publishing (Ad)Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 1, 2026 | globenewswire.comDamora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 1, 2026 | globenewswire.comDamora Therapeutics: Well-Funded Moonshot For CALR MutationsMay 27, 2026 | seekingalpha.comSee More Damora Therapeutics, Inc. Common Stock Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Damora Therapeutics, Inc. Common Stock? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Damora Therapeutics, Inc. Common Stock and other key companies, straight to your email. Email Address About Damora Therapeutics, Inc. Common StockGalecto Inc. is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue. Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders. In addition, Galecto is advancing a LOXL2 inhibitor, GB2064, in preclinical studies aimed at addressing unmet needs in hepatic and systemic fibrosis. These molecules leverage targeted delivery and selective inhibition strategies to modulate the fibrotic cascade and the tumor microenvironment. Founded in 2012, Galecto is headquartered in Copenhagen, Denmark, with research and development operations in Cambridge, Massachusetts. The company’s leadership team brings together expertise in molecular biology, medicinal chemistry and clinical development, with board members and executives drawn from both academia and the pharmaceutical industry. Galecto collaborates with academic centers and industry partners to advance its pipeline and explore additional indications for its proprietary inhibitors.View Damora Therapeutics, Inc. Common Stock ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Is Domino's Stock Serving Up a Buying Opportunity?Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud BetAmazon’s AI Spending Is About to Face Its Most Important AWS Test YetMarketBeat Week in Review – 07/13- 07/17Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to BenefitBank Earnings Are Roaring, But Wall Street Isn't Ready to CelebrateThe Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Upcoming Earnings Tesla (7/22/2026)Freeport-McMoRan (7/22/2026)Alphabet (7/22/2026)International Business Machines (7/22/2026)ServiceNow (7/22/2026)AT&T (7/22/2026)TE Connectivity (7/22/2026)Texas Instruments (7/22/2026)United Rentals (7/22/2026)Philip Morris International (7/22/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
